SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Orchestra Biomed Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

68572M106

(CUSIP Number)

___________December 31, 2022__________

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 68572M106

¹ The percentage reported herein reflects the Reporting Person’s beneficial ownership of shares of the Issuer’s Common Stock as of December 31, 2022. As of the date hereof, the Reporting Person no longer beneficially owns any shares of the Issuer’s Common Stock.

CUSIP No. 68572M106

² The percentage reported herein reflects the Reporting Person’s beneficial ownership of shares of the Issuer’s Common Stock as of December 31, 2022. As of the date hereof, the Reporting Person no longer beneficially owns any shares of the Issuer’s Common Stock.

CUSIP No. 68572M106

³ The percentage reported herein reflects the Reporting Person’s beneficial ownership of shares of the Issuer’s Common Stock as of December 31, 2022. As of the date hereof, the Reporting Person no longer beneficially owns any shares of the Issuer’s Common Stock.

CUSIP No. 68572M106

⁴ The percentage reported herein reflects the Reporting Person’s beneficial ownership of shares of the Issuer’s Common Stock as of December 31, 2022. As of the date hereof, the Reporting Person no longer beneficially owns any shares of the Issuer’s Common Stock.

Orchestra BioMed Holdings, Inc. (the “Issuer”).

40 10th Avenue, Floor 7, New York, New York 10014.

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

RA Capital Management, L.P. (“RA Capital”)

Peter Kolchinsky

Rajeev Shah

RA Capital Healthcare Fund, L.P. (the “Fund”)

The address of the principal business office of each of the Reporting Persons is:

c/o RA Capital Management, L.P., 200 Berkeley Street, 18^th Floor, Boston MA 02116.

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

Common Stock, par value $0.0001 per share (“Common Stock”).

68572M106.

Not applicable.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 11,212,117 total shares of Common Stock, as reported in the Issuer’s Prospectus Supplement with the Securities and Exchange Commission on December 16, 2022.

The beneficial ownership reported above reflects the Reporting Persons’ ownership as of December 31, 2022. As of the date hereof, the Reporting Persons no longer beneficially owns any shares of Common Stock.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolios, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Exhibit List

Exhibit 1: Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

EXHIBIT 1

AGREEMENT

This Joint Filing Agreement, dated as of February 14, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

Pursuant to and in accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file the foregoing statement on Schedule 13G with respect to the Common Stock, $0.0001 par value per share, of Orchestra BioMed Holdings, Inc. on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.